Overview

A Study of YL242 in Subjects With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Phase:
PHASE1
Details
Lead Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.
Treatments:
Fluorouracil
pembrolizumab